Mirum Pharmaceuticals Inc (MIRM)

Mirum Pharmaceuticals (MIRM) Stock Price & Analysis


MIRM Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$17.32 - $30.55
Previous Close$23.04
Average Volume (3M)314.45K
Market Cap
Enterprise Value$724.86M
Total Cash (Recent Filing)$151.72M
Total Debt (Recent Filing)$2.19M
Price to Earnings (P/E)-5.7
May 04, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.02
Shares Outstanding36,870,380
10 Day Avg. Volume238,986
30 Day Avg. Volume314,454
Standard Deviation0.41
Financial Highlights & Ratios
Price to Book (P/B)7.07
Price to Sales (P/S)17.87
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-10.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.41
Enterprise Value/Gross Profit11.21
Enterprise Value/Ebitda-5.92
Price Target Upside131.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?
Mirum Pharmaceuticals Inc lowest stock price was $17.32 and its highest was $30.55 in the past 12 months.
    What is Mirum Pharmaceuticals Inc’s market cap?
    Currently, no data Available
    When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?
    Mirum Pharmaceuticals Inc’s upcoming earnings report date is May 04, 2023 which is in 44 days.
      How were Mirum Pharmaceuticals Inc’s earnings last quarter?
      Mirum Pharmaceuticals Inc released its earnings results on Mar 08, 2023. The company reported -$0.99 earnings per share for the quarter, beating the consensus estimate of -$1.004 by $0.014.
        Is Mirum Pharmaceuticals Inc overvalued?
        According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Mirum Pharmaceuticals Inc pay dividends?
          Mirum Pharmaceuticals Inc does not currently pay dividends.
          What is Mirum Pharmaceuticals Inc’s EPS estimate?
          Mirum Pharmaceuticals Inc’s EPS estimate is -$0.82.
            How many shares outstanding does Mirum Pharmaceuticals Inc have?
            Mirum Pharmaceuticals Inc has 37,950,970 shares outstanding.
              What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?
              Mirum Pharmaceuticals Inc reported an EPS of -$0.99 in its last earnings report, beating expectations of -$1.004. Following the earnings report the stock price went down -1.01%.
                Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?
                Among the largest hedge funds holding Mirum Pharmaceuticals Inc’s share is Deerfield Management Company, LP. It holds Mirum Pharmaceuticals Inc’s shares valued at 40M.


                  Mirum Pharmaceuticals Stock Smart Score

                  The Mirum Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Mirum Pharmaceuticals Inc

                  Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  4D Molecular Therapeutics
                  POINT Biopharma Global
                  Anavex Life Sciences
                  iTeos Therapeutics
                  CTI BioPharma

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis